Longstanding evidence justifies the biological interest in NG2 as a potential surface marker involved in leukemia propagation and CNS involvement.14, 15 We have previously demonstrated that NG2 expression may be dependent on the cell of origin where a specific leukemic abnormality occurs.14 For instance, NG2 might be specifically regulated when leukemic drivers arise either in a specific lineage-committed progenitor or in a more immature hematopoietic stem cells. This evidence concerns the gene CSPG4 and leukemia.